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LETTER TO THE EDITORDifficulties in Monitoring the
Glucose Status of Patients
Undergoing Hematopoietic
Stem Cell Transplantation
We were pleased to read the article by Hammer
et al. in the March edition of BBMT [1], which comple-
ments and vastly expands on our earlier abstract [2].
Recognizing the need for a prospective randomized
clinical trial to provide more insight into the relation-
ship between transplantation mortality/morbidity and
glycemia control, we embarked on such a trial in 2007.
We randomized patients undergoing hematopoietic
stem cell transplantation (HSCT) to ‘‘tight’’ blood
glucose control, with a goal of\125 mg/dL, using
insulin/glucose infusions and the best available ‘‘real-
time’’ glucose monitoring system (Guardian REAL-
Time Monitor; Medtronic, Minneapolis, MN) versus
a traditional insulin sliding scale. Our transplantation
unit’s nurses underwent extensive training in glucose
management using the monitor, and our local
Medtronic representative provided excellent onsite
support. In addition, a diabetologist evaluated the
study patients during daily rounds. Unfortunately,
despite these efforts, we were unable to complete the
trial. The Medtronic device was unable to provide
reliable, actionable glucose readings in the inpatient
transplantation setting. This lack of reliability in glu-
cose readings resulted in the need for frequent finger-
sticks to recalibrate and validate the monitoring
device. Patients found this bothersome, and some
eventually withdrew consent to participate in the
study. This problem was addressed in the device’s
Food and Drug Administration approval document,
with the admonishment that monitor ‘‘values are not
to be used directly for making therapy adjustments.’’
More worrisome than the frequent fingersticks were
the numerous episodes of asymptomatic and symp-
tomatic hypoglycemia occurring in patients assigned
to the ’’tight’’ glucose control regimen. These episodes1000were considered secondary to the fluctuations of oral
intake seen as patients experienced gastrointestinal
distress, mucositis, and corticosteroid use, making it
very difficult to anticipate their insulin needs and safely
maintain a blood glucose level\125 mg/dL.
The unacceptably high rate of hypoglycemia, in
combination with the technical limitations inherent
with the implantable real-time glucose monitor, led
to the termination of our trial. We would caution other
investigators that the available real-time implantable
glucose monitoring device remains unapproved and
inadequate by itself for monitoring the blood glucose
levels of patients undergoing HSCT.ACKNOWLEDGMENTS
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